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CC BY-NC-ND license (http://creativeBackground/Purpose: Parkinson’s disease (PD) is the second most common neurodegenerative
disorder worldwide. Although idiopathic PD accounts for most of the cases, several genetic mu-
tations have been found to cause PD. Mutations in the eukaryotic translation initiation factor 4-
g, 1 (EIF4G1) gene have been identified since 2011, which were reported to be associated with
PD among Caucasians in subsequent research. However, this observation was not consistent.
The contribution to other ethnic groups remains limited, with < 1% of sporadic cases. We con-
ducted a caseecontrol study to analyze if EIF4G1 is a risk factor for PD patients in Taiwan.
Methods: There were 595 PD patients and 600 controls without neurological diseases enrolled
in this study. Four reported mutationsdA502V (c.1505C>T), G686C (c.2056 G>T), R1197W
(c.3589C>T), and R1205H (c.3614G>A)dwere analyzed.
Results: There were no mutations found in either PD patients or controls.
Conclusion: This study indicates that the EIF4G1mutation is rare in Taiwan, which is consistent
with other reports from Asia. Ethnicity could have a great influence on EIF4G1 in PD. Further
large scale studies are warranted to evaluate the association of PD and EIF4G1 gene.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder with cardinal features ofhave no conflicts of interest relev
t of Neurology, Chang-Gung Mem
aiwan.
h.org.tw (Y.R. Wu).
5.07.020
an Medical Association. Published
commons.org/licenses/by-nc-ndresting tremor, rigidity, bradykinesia, and postural insta-
bility.1 Idiopathic PD accounts for most cases, butw5e10%
of PD could be caused by gene mutation.2 Several of these
Mendelian-transmitted mutations have been identified suchant to this article.
orial Hospital and Chang-Gung University College of Medicine, 199
by Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
EIF4G1 gene mutations are rare in Taiwan 729as SNCA, which accounts for PARK1 and PARK4,3 PRKN for
PARK2,4 PINK1 for PARK6,5 DJ-1 for PARK7,6 LRRK2 for
PARK8,7 and ATP13A2 for PARK9.8 In 2011, Chartier-Harlin
et al9 identified a new missense mutation R1205H
(c.3614G>A) in the eukaryotic translation initiation factor
4-g, 1 (EIF4G1) gene in one French family. Subsequent
sequence and genotype analysis identified EIF4G1 A502V
(c.1505C>T), G686C (c.2056 G>T), S1164R (c.3490A>C),
and R1197W (c.3589C>T) substitutions in affected patients
with familial parkinsonism and idiopathic Lewy body dis-
ease but not in control individuals.9 Later, several EIF4G1
mutation/variants were investigated for association with
PD.10e23 However, the results did not confirm these genetic
associations.
EIF4G1, a protein scaffold subunit of the translation
initiation complex, binds the ribosomal 40S. A decrease of
EIF4G1 level in cells results in a reduction of overall protein
synthesis linked to nutrient perception.24 Pathogenic
EIF4G1 substitutions, A502V and R1205H, have been
demonstrated to disrupt binding to EIF4E and EIF3E,
respectively, and thus lead to mitochondrial dysfunction.9
By contrast, overexpression of EIF4G1 protein has been
implicated in cell proliferation as observed in some malig-
nant disorders.25 Furthermore, in a yeast model, a EIF4G1
ortholog (TIF4632) may reduce a´-synuclein toxicity.26 Taken
together, this evidence suggests that EIF4G1 may play a
role in PD regarding maintaining mitochondrial function and
cell survival as well as protecting against neuron damage
from accumulated a´-synuclein.
In Taiwan, the link between EIF4G1 variants and PD has
not been investigated. Here we conducted the first EIF4G1
genetic study in the Taiwanese population and tried to
determine the frequency of EIF4G1 variants among PD pa-
tients to clarify the association between EIF4G1 variants
and PD.
Methods
Patients
For this study, 595 patients diagnosed with PD were
recruited from the neurology clinics of Chang-Gung Memo-
rial Hospital, Taipei, Taiwan. Only the probands of each
familial PD family were included in the study. The diagnosis
of PD was based on the modified UK Parkinson’s disease
society brain bank clinical diagnostic criteria.27 In addition,
600 unrelated adult volunteers without neurological dis-
eases matched for age, sex, ethnic origin, and area of
residence were recruited as controls. All participants gave
informed consent for the study under a protocol (No. 101-
2599A3) approved by hospital internal ethics and scientific
boards.
Genotyping and data imputation
DNA was extracted from peripheral blood by standard
protocols. Four mutations of the EIF4G1 genedA502V,
G686C, R1197W, and R1205Hdwere investigated. These
mutations, firstly found in 2011 by Chartier-Harlin et al,9
were the most common screened mutations to be pub-
lished in subsequent literature.10e23 Although S1164R wasalso identified in 2011,9 it was not included because there
was no positive finding in these studies.10e23
The genotyping was performed by Sequenom MassARRAY
platform with iPLEX gold chemistry (Sequenom, San Diego,
CA, USA). By following the manufacture guide, the specific
polymerase chain reaction (PCR) primer and extension
primer sequences are designed with Assay Designer soft-
ware package (version 4.0, Sequenom MassARRAY system).
The primers used for PCR amplification are listed in Table 1.
One mL of Genomic DNA sample (10 ng/mL) was applied to
multiplex PCR reaction in 5 mL volumes containing 1 unit of
Taq polymerase, 500 nmol of each PCR primer mix and
2.5 mM of each dNTP (PCR accessory and Enzyme kit,
Sequenom). Thermocycling was at 94C for 4 minutes fol-
lowed by 45 cycles of 94C for 20 seconds, 56C for 30 sec-
onds, and 72C for 1 minutes, then 72C for 3 minutes.
Unincorporated dNTPs were deactivated using 0.3 U of
shrimp alkaline phosphatase. The single base extension
reaction was using iPLEX enzyme, terminator mix, and
extension primer mix followed by 94C for 30 seconds fol-
lowed by 40 cycles of 94C for 5 seconds, and five inner
cycles of 56C for 5 seconds and 80C for 5 seconds, than
72C for 3 minutes (iPLEX gold kit, Sequenom). After the
addition of a cation exchange resin to remove residual salt
from the reactions, 7 nL of the purified primer extension
reaction was loaded onto a matrix pad of a SpectroCHIP
(Sequenom). SpectroCHIPs were analyzed using a MassAR-
RAY Analyzer 4 (Sequenom), and the calling by clustering
analysis with TYPER 4.0 software (Sequenom).
Results
The mean age of 595 PD patients was 64.8  10.2 years, and
the mean age at onset of PD symptoms was
62.7  11.3 years; 45% were women. The age at recruit-
ment of 600 controls was 59.1  12.7 years; 53% were
women. Statistically, both groups demonstrated equal age
of recruitment, age at onset, and sex distribution. There
were 21 patients with PD family history and 120 patients
with age at onset younger than 50 years. All familial PD
patients have screened for LRRK2 variants, which found
LRRK2 R1441H mutation in one patient. Additionally, two
sporadic patients with age at onset at age < 50 years car-
rying PARK2 deletions (Ex2-3del and Ex5del, respectively).
Four selected mutations of EIF4G1 described in the method
were examined. Our study revealed that EIF4GI A502V,
G686C, R1197W, and R1205H were all absent in both pa-
tients and normal controls. This finding indicated that these
mutations are rare among PD patients in Taiwan.
Discussion
In 2011, EIF4G1 gene was first described to be a possible
gene accounting for late onset, autosomal dominant PD in
Caucasian populations by Chartier-Harlin et al.9 R1205H
was identified initially in a French family with PD. The
parkinsonian feature in this family was a relatively long
course, mild symptom, and preserved cognition. R1205H
was further investigated and found in seven PD families
from USA, Canada, Ireland, Italy, and Tunisia.9 Other
EIF4G1 variants including A502V, G686C, S1164R, and
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730 Y.C. Weng et al.R1197W were also found from the USA, France, and Poland
PD families.9 Among them, A502V and G686C were also
found from idiopathic PD patients.9 Functional analyses
have shown that EIF4G1 A502V and R1205H disrupt EIF4E
or EIF3E binding, increasing their susceptibility to reactive
oxidative species.9
Recently, a study from the French PD genetic study
group found R1197W in a control individual, but not in PD
patients, suggesting that R1197W may not be a causative
mutation for PD.10 In another study from central Europe,
five PD cases carrying G686C mutation were identified, but
this variant was also found in three normal controls.11
Additionally, R1205H was present in healthy controls but
not in cases in the same study.11 After its first report in
2011,9 R1205H has been identified in some patients from
America via whole exome sequencing13 but only one pa-
tient from a most recent large European cohort study.12 By
contrast, R1205C rather than R1205H was identified in one
patient from southwest China.21 Due to the conflicting
results listed above, the importance of EIF4G1 mutations
in PD remains doubtful. The possible explanations for
identification of mutants in controls include the possibility
of development of PD in the future, incomplete pene-
trance, or the mutation conferring a risk for PD. The
summary of previous reports about EIF4G1 is listed in
Table 2.
From our study, EIF4G1 mutations were not observed
among PD patients and controls. The result was reminis-
cent of other studies in different countries such as China,
Singapore, Japan, South Africa, India, and Italy, all of
which showed negative findings.14e20,22 Possible reasons
could be: first, EIF4G1 gene mutations could be mutation
in PD, so study of more PD patients is warranted. Sec-
ondly, the first reported cases were from Caucasians and
subsequent positive results were mostly European or
American. Only one Chinese PD patient with EIF4G1
R1205C mutant was found in a recent study,21 and other
mutations were not observed among other Asian pop-
ulations.14e17,22 Ethnicity may have a significant influence
on the negative results. Furthermore, it may also be
possible that western and eastern patients had different
prevalent mutation variants, and thus it is difficult to find
EIF4G1 mutation in the Eastern population if only
screening previously identified mutations. For example,
T355I (c.1064C>T) was recently been found in one Asian
descent23 and also in AfricaneAmerican people found in
the European American population.13 The important role
of ethnicity in PD had been discussed in previous study.28 A
good example is leucine-rich repeat kinase 2 gene (LRRK2)
G2019S variant is the most common mutation for Cauca-
sian PD patients, but it is rare for Asians.28e32 By contrast,
G2385R variant is a genetic risk factor for Asian PD pa-
tients but very rare for Caucasian patients.28,33e37 Be-
sides, the microtubule-associated protein tau gene
r393152 variant on the locus has been shown to be a risk
factor for PD in Caucasians as compared to Asians.28 Ge-
netic variants of bone marrow stromal cell antigen gene
and PARK16 also have an ethnic difference.28
The limitation of this study is that we only screened
A502V, G686C, R1197W, and R1205H rather than
sequencing all exons and exoneintrons of EIF4G1 gene. It
would be possible to miss novel mutations in our study.
Table 2 Summary of EIF4GI studies. The table listed the year of published literature and screened method. The result of variants are also listed.
Published year Authors Screened method Positive result from patients Number of PD patients
(F:S)b
Ethnic population Refs
2012 Schulte et al Sequencing exons & exoneintron
boundaries
A502V, G686C, S1164R, R1205H
Multiple, include G686C 376
975 (557:418)a
European 11
2012 Lesage et al Sequencing exons & exoneintron
boundaries
Multiple, include G686C 251 (251:0) European 10
2012 Tucci et al Sequencing exon 8 & exon 22 P486S 150 (150:0) European 20
2013 Nuytemans et al Whole exome sequencing Multiple, include R1205H 213 (25:188) Caucasian,
non-Hispanic/
Latino descent
13
2013 Li et al Sequencing exons & exoneintron
boundaries
T161A, M432V, R1205H
T161A, M432V 29 (29:0)
503 (0:503)
Chinese 14
2013 Zhao et al Sequencing exons & exoneintron
boundaries
M432V, P693S
M432V, P693S 96 (75:21)
791
Chinese
Mixed Asian races
15
2013 Yuan et al 502V, R1205H no 425 (119:306) Chinese 16
2013 Sudhaman et al Sequencing coding exons
R1205H
no 15 (15:0)
305 (54:251)
Indian 22
2013 Chen et al R1205H R1205C 609 (37:572) Southwest Chinese 21
2013 Siitonen et al Sequencing coding region T355I, R1172_D1174del 168 Caucasian
Asian
African American
American Indian
Pacific Islander
Other
23
2014 Nishioka et al Sequencing coding exons
A502V, R1205H
No 95 (95:0)
224 (43:181)
Japanese 17
2014 Blanckenberg et al R1205H No 418 (0:418) Caucasian
non-Afrikaner
Caucasian Afrikaner
Mixed ancestry
African
Indian
18
2014 Gagliardi et al R1205H No 250 (250:0) European 19
2015 Huttenlocher et al Sequencing coding region
A502V, R1205H
Multiple, include R1205H 95 (95:0)
2051 (0:2051)
European 12
a There were 376 patients included in group of sequencing exons and exoneintron boundaries.
b F:S Z familial:sporadic.
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732 Y.C. Weng et al.Although there was no EIF4G1 A502V, G686C, R1197W, and
R1205H mutation found in our study, this observation does
not exclude other variants in the EIF4G1 gene that may
cause PD in Taiwan. Further investigations including whole
gene sequencing and recruiting a large sample size of pa-
tients with PD from diverse populations, as well as studies
of EIF4G1 expression and in scaffold function, are required
to evaluate the association between PD and EIF4G1 gene.Acknowledgments
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